Payment overview · 2025
General Payments
$741.65
33 reported records · 14 companies
Healthcare provider profile · identity verified
David M. Heller, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN DIEGO, CA · NPI 1639274251
Verified facts
What the public records show
CMS Open Payments records show David M. Heller, M.D. received $741.65 in general payments during 2025 across 33 reported records.
Amgen Inc. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $221.59 | 29.9% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.83 | 12.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.76 | 10.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.35 | 8.3% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $52.49 | 7.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.42 | 6.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.36 | 4.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.94 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.78 | 3.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.15 | 3.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $24.05 | 3.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.33 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.79 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.81 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $741.65 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $149.24 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.76 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $72.35 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $72.35 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.17 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.35 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $52.49 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.36 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.66 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $5.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 123 |
| Losartan Potassium | Losartan Potassium | 336 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 58 |
| Alprazolam | Alprazolam | 158 | 46 |
| Simvastatin | Simvastatin | 136 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 43 |
| Gabapentin | Gabapentin | 123 | 40 |
| Lorazepam | Lorazepam | 111 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 34 |
| Allopurinol | Allopurinol | 88 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 32 |
| Metformin Hcl | Metformin Hcl | 81 | 28 |
| Benazepril Hcl | Benazepril Hcl | 75 | 22 |
| Eliquis | Apixaban | 70 | 22 |
| Trazodone Hcl | Trazodone Hcl | 70 | 26 |
| Lisinopril | Lisinopril | 69 | 24 |
| Alendronate Sodium | Alendronate Sodium | 67 | 19 |
| Clonazepam | Clonazepam | 67 | 15 |
| Valsartan | Valsartan | 67 | 22 |
| Furosemide | Furosemide | 60 | 14 |
| Omeprazole | Omeprazole | 60 | 22 |
| Jardiance | Empagliflozin | 57 | 14 |
| Metformin Hcl Er | Metformin Hcl | 54 | 20 |
| Ezetimibe | Ezetimibe | 53 | 17 |
| Potassium Chloride | Potassium Chloride | 52 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 51 | suppressed |
| Meloxicam | Meloxicam | 48 | 15 |
| Synthroid | Levothyroxine Sodium | 48 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 22 |
| Sertraline Hcl | Sertraline Hcl | 45 | 15 |
| Finasteride | Finasteride | 42 | 17 |
| Bupropion Xl | Bupropion Hcl | 40 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 13 |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 32 |
| Ozempic | Semaglutide | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 14 |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 13 |
| Famotidine | Famotidine | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | 11 |
| Estradiol | Estradiol | 26 | 12 |
| Prednisone | Prednisone | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 14 |
| Ketoconazole | Ketoconazole | 23 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | 11 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Atenolol | Atenolol | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Avapro | Irbesartan | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $741.65 · 33 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GARDASIL 9, INJECTAFER, OTEZLA, PREVNAR 20, PROLIA, QULIPTA, REPATHA, SHINGRIX, SYMPLICITY G3, TRELEGY ELLIPTA, UBRELVY, VAXELIS, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error